Abstract IA003: Targeting the antigenic landscape that emerges after KRAS inhibition for PDAC immunotherapy
Targeting the antigenic landscape that emerges after KRAS inhibition for PDAC immunotherapy holds significant translational potential as KRAS inhibitors are poised to become a mainstay in PDAC treatment and treatment induced antigens may serve as the foundation for rationally designed combination immunotherapies.